MIT Researchers May Have Found Cure for the Common Cold, Other Viruses
August 29, 2011 9:22 PM
The left panel shows treated and untreated cells in regards to the common cold virus (rhinovirus) while the right panel shows treated and untreated monkey cells in regards to dengue hemorrhagic fever virus
(Source: Massachusetts Institute of Technology)
Double-stranded RNA Activated Caspase Oligomerizers (DRACOs) could be the answer for terminating viruses like H1N1 influenza, stomach viruses, a polio virus, several types of hemorrhagic fever and dengue fever
Viruses like the common cold and influenza are infections that we occasionally must ride out. All anyone can really do is rest and take medications to ease the symptoms, which can range from congestion to fever to vomiting. Other viruses, such as
, can be potentially fatal due to Ebola hemorrhagic fever.
While many bacterial infections can be treated with antibiotics, not many viral infections can be treated with medications. Only a "handful" can fight viruses, like the protease inhibitors to
, but most other treatments only relieve the symptoms, and even that can take several days in some cases. Viruses are difficult to attack because they change and replicate in healthy cells.
But now, a team of researchers at MIT's Lincoln Laboratory
may have found the cure
for the common cold as well as many other viruses like H1N1 influenza, stomach viruses, a polio virus, several types of hemorrhagic fever and dengue fever. The team, led by Todd Rider, a senior staff scientist in Lincoln Laboratory's Chemical, Biological and Nanoscale Technologies Group, created therapeutic agents called Double-stranded RNA Activated Caspase Oligomerizers (DRACOs) which have successfully terminated viral infections.
Viruses infect cells
by taking over the cell entirely and multiplying. While making copies of themselves, the viruses also produce long strings of double-stranded RNA (dsRNA). This is not found in animal or human cells.
To fight these infected cells, healthy human cells have proteins that bind to dsRNA, which then prompts a series of reactions that work to stop the virus from making copies of itself. The problem is that the virus can block one of the healthy cells' series of steps to prevent its replication somewhere down the line, allowing the virus to change and further reproduce once again.
To remedy this problem, Rider and his team mixed a dsRNA protein with another protein that causes cells to go through apoptosis, which is programmed cell suicide. One end of the DRACO binds to dsRNA while the other end is instructed to launch cell suicide.
Also, each DRACO consists of a "delivery tag" that they received from naturally occurring proteins. This allows it to enter any human or animal by crossing cell membranes, meaning that it can combat a broad spectrum of viruses, possibly including new outbreaks.
The team tested the DRACOs in human and animal cells cultured in the lab as well as mice infected with the H1N1 influenza virus. They found that DRACO left the mice fully cured of the infection, and that DRACO is not toxic to these animals. In addition, DRACO only targeted cells with dsRNA present while leaving healthy cells alone.
Rider and his team are now testing DRACO on other viruses in mice, and hope to eventually test it on larger animals and humans.
was published in
"If you mod me down, I will become more insightful than you can possibly imagine." -- Slashdot
Research Team Discovers How Ebola Virus Enters, Replicates in a Host Cell
August 25, 2011, 4:50 PM
New Virus Leads Drugs to HIV-Infected Cells
August 9, 2011, 1:20 PM
Mountain Gorillas Infected by Human Virus for the First Time
March 29, 2011, 6:28 PM
PIQ ROBOTTM reveals its new artificial intelligence software
November 29, 2016, 12:59 AM
One more time - Happy Thanksgiving to Everyone Around the World
November 24, 2016, 4:00 AM
Google’s Smart Contact Lens Project gets halted for 2016
November 20, 2016, 7:00 AM
Cell Research Study shows African Americans have greater immune response to infection
November 10, 2016, 1:00 AM
UTHealth Clinical Trial Shows Progress Using Stem Cells to Treat Traumatic Brain Injury
November 8, 2016, 1:00 AM
Uber Partners with Circulation to Pilot Program Connecting Transportation and Digital Health Care
November 6, 2016, 5:00 AM
Most Popular Articles
Samsung Galaxy S8, Rumored Launch Date!
March 18, 2017, 6:45 AM
Gigabyte GA-Z170X-Gaming G1 – Intel Thunderbolt 3 Certified Motherboard
March 9, 2017, 6:25 AM
Lenovo ThinkPad T460 - Ultra-Thin and Feather-light
March 3, 2017, 6:00 AM
Huawei P8 Lite 2017 – Android 7 Nougat Smartphone with Octa-Core Processor
March 8, 2017, 7:03 AM
Intel Optane SSd DC P4800X – Super Fast 3D Storage
March 20, 2017, 7:35 AM
Latest Blog Posts
Are you thinking of performance and speed? Intel claims:
Mar 25, 2017, 7:45 AM
Apple buys an automation app called Workflow. The deal was completed today and brings the app along with its developers.
Mar 23, 2017, 7:35 AM
Apple Announces new color for iPhones and iPads
Mar 22, 2017, 7:45 AM
Instagram: You Can Now Save Live Videos For Later
Mar 21, 2017, 7:49 AM
Samsung Galaxy S8 to Get New Color Scheme
Mar 20, 2017, 7:45 AM
What else to worry about?
Mar 17, 2017, 6:45 AM
Icon of the Day: Intel/ NVIDIA or Mobileye
Mar 16, 2017, 6:15 AM
JUST IN - Twitter Hijacked : High-Profile Account Accesses
Mar 15, 2017, 7:07 AM
Mar 14, 2017, 7:30 AM
News and Tips
Mar 13, 2017, 6:30 AM
iPhone 8 – May Not Get Curved Screen
Mar 11, 2017, 8:00 AM
California paves way to self-driving car tests without humans
Mar 11, 2017, 7:18 AM
Smart Machines V hackers
Mar 10, 2017, 7:00 AM
Uber Can Resume Autonomous Car Testing in California
Mar 9, 2017, 6:50 AM
Mar 8, 2017, 7:09 AM
Mar 7, 2017, 8:45 AM
World news 3-6
Mar 6, 2017, 5:40 AM
Mar 4, 2017, 7:40 AM
Mixed News of the Day
Mar 4, 2017, 6:32 AM
Jaguar Land Rover invests in ride-sharing
Mar 3, 2017, 7:00 AM
Mixed News of The World:
Mar 2, 2017, 7:02 AM
World New 3-1
Mar 1, 2017, 6:30 AM
More Blog Posts
Copyright 2017 DailyTech LLC. -
Terms, Conditions & Privacy Information